Home About Us Pipeline News Investors Contacts Careers




Puma Biotechnology, Inc. Corporate Fact Sheet


RECENT NEWSCURRENT EVENTSCLINICAL TRIALS



December 14, 2017 - Puma Biotechnology Added to NASDAQ Biotechnology Index
Read

December 13, 2017 - Puma Biotechnology Announces Meeting of Scientific Advisory Group on Oncology in Europe to Review Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read

December 12, 2017 - Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
Read

December 11, 2017 - Puma Biotechnology Announces Positive Outcome of European Opposition Proceedings
Patent Claims for Extended Adjuvant Treatment Upheld
Read

December 6, 2017 - Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 San Antonio Breast Cancer Symposium
Read

December 5 – 9, 2017 - San Antonio Breast Cancer Symposium
More

November 15, 2017 - Stifel 2017 Healthcare Conference
More

November 9, 2017 - Puma Biotechnology 3Q-2017 Financial Results
More

November 7, 2017 - Credit Suisse Healthcare Conference
More

Puma-Sponsored Trials
Investigator-Sponsored Trials




Annual Report

2016 Annual Report

 Annual Report Archives



Contact

Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax
info@pumabiotechnology.com